Lymphoma News Archive
Eighteen and 127 patients were enrolled into dose-escalation and dose expansion cohorts, respectively.
No PFS or OS events were reported for treatment-naive elderly patients.
A variety of cognitive impairments are common in the elderly US population, with as many as 14% of individuals over 70 being affected by dementia.
The most frequently reported grade 3 to 4 adverse events included neutropenia, infection, and cutaneous toxicity. Three treatment-related deaths (2 from sepsis and 1 from embolic stroke) were noted.
Short-term incidence of leukemia, lymphoma, and brain cancer may be higher in children who were hospitalized with pneumonia.
Patients treated with BEACOPP have improved outcomes compared with ABVD but also face significant adverse events. A major goal of therapy is therefore to minimize toxicity.
The median PFS was significantly longer in the R-B arm: 15.0 years compared with 11.7 years in the R-CHOP arm.
With improving supportive care, elderly patients may benefit from high-dose chemotherapy with autologous stem cell transplantation.
Patients who received the recommended phase 1 dose of brentuximab vedotin and bendamustine had an overall response of 78%.
Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.
Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.
The median time to response (TRR) was 1.9 months. The median duration of response (DoR) was not reached, though the 12-month DoR rate was 72% (95% CI, 62-80%).
Patients who did not reach a first complete remission were twice as likely to fail rituximab maintenance therapy; patients who received autologous stem cell transplant had a decreased failure risk of 69%.
Ibrutinib is used among patients with WM who have previously received treatment, but its efficacy as a first-line therapy among treatment-naive patients is unknown.
The purpose of this study was to assess the benefit of brentuximab vedotin, an effective and well-tolerated agent for relapsed cHL, when added to standard eBEACOPP.
Brentuximab Vedotin Approved for Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-expressing Mycosis Fungoides
The U.S. Food and Drug Administration has approved brentuximab vedotin for the treatment of adult patients with pcALCL or CD30-expressing mycosis fungoides who have received prior systemic therapy.
An interim analysis of a cohort in the CheckMate-205 study showed that nivolumab had an acceptable safety profile and demonstrated efficacy among patients with relapsed and refractory classical Hodgkin lymphoma after post-auto-HCT brentuximab vedotin.
The open-label, multicenter, phase 3 FOLL05 trial included untreated patients with grade 1, 2, or 3a and Ann Arbor stage II to IV disease. This analysis included 504 evaluable patients.
The FDA based its approval on evidence from the single-arm, LY-004 clinical study, for which researchers enrolled 124 patients with MCL to receive acalabrutinib 100 mg twice daily.
Previous study suggests that EFS is a prognostically relevant variable among patients with other lymphomas; for this study, researchers evaluated whether EFS24 predicts for overall survival in PTCL.
FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
Despite high efficacy, the $373,000 list price from the drug's manufacturer may preclude some patients from receiving axicabtagene ciloleucel.
The FDA granted Breakthrough Therapy Designation to brentuximab vedotin plus chemotherapy as first-line therapy for advanced classical Hodgkin lymphoma.
The FDA granted accelerated approval to copanlisib for the treatment of adult patients with relapsed follicular lymphoma who have received at least 2 prior treatments.
Patients with untreated FL were randomly assigned to receive cyclophosphamide, vincristine, and prednisone (CVP) plus rituximab (R) or GP2013 for 8 cycles followed by 2 years of monotherapy maintenance in patients who responded to treatment.
Researchers evaluated the outcomes of patients with HL who received HAPLO, SIB, or MUD transplantations.
At the median follow-up 22.9 months, 56.3% of patients in the BV arm achieved a significantly superior objective global response lasting at least 4 months vs 12.5% of patients in the IC arms.
Researchers enrolled 1418 patients with previously untreated DLBCL and randomly assigned them to receive G-CHOP or R-CHOP.
In patients with R/R WM, the overall response rate was 87%, with 4% of patients achieving a very good partial response.
Researchers enrolled 17,202 individuals, half of whom were cancer survivors and half of whom were healthy controls, to compare opioid prescription rates between the 2 groups.
Researchers enrolled patients with FL to investigate the cumulative incidence of HT, risk factors associated with HT, and the role of treatment and response on survival following transformation.
The FDA granted Breakthrough Therapy Designation to acalabrutinib for patients with MCL who have received at least 1 line of therapy.
The phase 3 REMARC study enrolled 650 treatment-naive patients with DLBCL or other aggressive B cell lymphomas.
Concordant BM involvement in patients diagnosed with diffuse large B cell lymphoma is associated with worse clinical outcomes.
The FDA granted approval to rituximab and hyaluronidase human as a subcutaneous injection for the treatment of follicular lymphoma, chronic lymphocytic leukemia, and DLBCL.
Universal vaccination against hepatitis B virus infection prevented non-Hodgkin lymphoma in adolescents in Taiwan, an endemic area for hepatitis B virus infection.
Brentuximab vedotin significantly prolonged PFS with higher response rates compared with methotrexate or bexarotene among patients with CTCL.
Rituximab's mechanism of action may reduce immune surveillance, allowing for the proliferation of cancer cells and infectious agents.
Patients with chronic lymphocytic leukemia younger than age 55 are at an increased risk for multiple types of secondary cancers for up to 15 years after diagnosis.
Ibrutinib provides long term survival benefits to patients with chronic lymphocytic leukemia regardless of cytogenetic risk factors.
Fludarabine and rituximab plus lenalidomide results in durable prolonged PFS compared with FR or FR plus cyclophosphamide among patients with untreated chronic lymphocytic leukemia.
Availability of important services and adequacy of care are among the factors explaining low numbers of patients with hematologic cancers being referred for hospice care.
Patients with DLBCL were at an increased risk of non-cancer-related deaths from blood disease, infection, gastrointestinal disease, vascular diseases, and lung disease.
Subcutaneous rituximab has similar efficacy and safety as the intravenous formulation for the first-line treatment of follicular lymphoma.
Pembrolizumab treatment resulted in high ORRs among patients with relapsed/refractory classic Hodgkin lymphoma regardless of previous therapy.
TET2 loss may indirectly cause several hematologic malignancies, including myeloid, T cell, and B cell cancers.
Data suggest that lenalidomide maintenance for 24 months can prolong PFS among elderly patients with DLBCL, but does not improve overall survival.
Two SNPS (rs4880 and rs1870377) had an association with PFS among patients with DLBCL receiving R-CHOP.
Glucocorticoid-containing chemotherapy may induce diabetes mellitus or worsen glucose control among patients with diffuse large B cell lymphoma.
Survivors with a family history of colorectal, breast, and lung cancer were at a significantly higher risk of similar second cancers.
PD-1 blockade with nivolumab was active in patients with Hodgkin lymphoma who received allogeneic hematopoietic cell transplantation.
Adjusting treatment dose after 2 courses of first-line therapy based on a positive PET scan does not improve progression-free survival.
Treatment with anthracyclines increases the risk for developing heart failure by 3-fold independently of radiation dose among survivors of Hodgkin lymphoma.
The FDA has granted accelerated approval to ibrutinib (Imbruvica) for the treatment of patients with relapsed/refractory marginal zone lymphoma.
Venetoclax was well-tolerated with variable efficacy against various non-Hodgkin lymphoma (NHL) subtypes.
Patients with diffuse large B-cell lymphoma (DLBCL) who achieved post-treatment event-free survival for 24 months had only a minimally lower life expectancy.
Allogeneic HSCT following treatment with an anti-PD-1 monoclonal antibody appears feasible in patients with relapsed/refractory lymphoma.
For relapsed or refractory diffuse large B-cell lymphoma (DLBCL), there is no difference in efficacy between ofatumumab or rituximab.
Thirty-month complete response is an accurate predictive endpoint for progression-free survival in follicular lymphoma clinical trials.
Rapid administration of rituximab over 90 minutes was safe and feasible for patients with primary central nervous system (CNS) lymphoma.
Elderly patients with diffuse large B-cell lymphoma ineligible for transplantation may benefit from radioimmunotherapy after chemoimmunotherapy.
Obinutuzumab-based induction and maintenance chemoimmunotherapy significantly improved progression-free survival.
Treatment with brentuximab vedotin is associated with superior clinical outcomes compared with standard of care options.
Chemotherapy-free induction with ibrutinib and rituximab is efficacious and well-tolerated among young patients.
Rituximab maintenance following autologous hematopoietic cell transplantation prolongs survival among younger patients with mantle cell lymphoma.
Brentuximab vedotin in combination with RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) is active as a frontline therapy.
Ultra-high risk category of patients with diffuse large B-cell lymphoma (DLBCL) who have dismal outcomes on existing therapies.
Clonal hematopoiesis at the time of primary cancer diagnosis was associated with a significantly increased risk of therapy-related myeloid neoplasm development.
The FDA has granted Priority Review to a sBLA that is seeking approval for pembrolizumab (Keytruda) for the treatment of Hodgkin lymphoma.
Lenalidomide plus rituximab may be more effective for the treatment of mucosa-associated lymphoid tissue lymphoma (MALT lymphoma).
Treatment with nivolumab (Opdivo) resulted in an encouraging response rate in an expanded population of patients with classical Hodgkin lymphoma.
Patients with double-hit lymphoma (DHL) or double-expressor lymphoma (DEL) have inferior outcomes following autologous stem cell transplantation (ASCT).
Targeting uracil-DNA glycosylase (UNG) may help to prevent the onset and proliferation of B-cell lymphoma.
Treatment with cyclophosphamide, vincristine, and prednisolone (CVP) significantly improved progression-free survival.
Lenalidomide induced clinically meaningful antitumor activity among patients with relapsed or recurrent aggressive adult T-cell leukemia/lymphoma (ATL).
Baseline total metabolic tumor volume is associated with treatment outcomes for patients with high-tumor-burden follicular lymphoma.
The phase 3 ALCANZA study evaluating brentuximab vedotin (Adcetris) met its primary endpoint.
Total metabolic tumor volume is effective for determining the prognosis of high-tumor-burden follicular lymphoma.
Non-Hodgkin lymphoma (NHL) and Kaposi's sarcoma may be more likely to occur in HIV-infected patients with higher CD4 counts and lower HIV RNA values.
Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (AVD) followed by involved-site radiotherapy (ISRT) was efficacious.
Nivolumab induced frequent responses with an acceptable safety profile for patients with classical Hodgkin lymphoma.
The phase 3 GOYA study for patients with previously untreated diffuse large B-cell lymphoma (DLBCL) failed to meet its primary endpoint.
Bendamustine, Gemcitabine, Vinorelbine Promising Treatment for Relapsed or Refractory Hodgkin Lymphoma
BeGEV appears to provide clinical benefit for patients with relapsed or refractory Hodgkin lymphoma, and ought to be developed further.
Adding Obinutuzumab to Bendamustine Clinically Beneficial for Patients With Rituximab-refractory NHL
Obinutuzumab plus bendamustine followed by obinutuzumab maintenance significantly improved progression-free survival.
Patients with advanced Hodgkin lymphoma may benefit from positron-emission tomography-computed tomography (PET-CT) testing.
Everolimus administered for 14 days in combination with R-CHOP is feasible for the treatment of patients with diffuse large B-cell lymphoma (DLBCL).
Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Obinutuzumab was superior to rituximab with respect to progression-free survival in patients with previously untreated follicular lymphoma.
Gonadotropin-releasing hormone agonist (GnRHa) may not be efficient in preventing chemotherapy-induced premature ovarian failure (POF).
The FDA has granted accelerated approval to nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma.
Among patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), 28% of patients achieved a response with panobinostat.
Safety and feasibility of CD19 CAR TCM therapy post-myeloablative HSCT were established in non Hodgkin lymphoma.
ABVD and BEACOPP resulted in similar event-free survival and overall survival in patients with high-risk advanced-stage Hodgkin lymphoma.
Investigational antibody-drug conjugate shows significant activity in patients with indolent B-cell non-Hodgkin lymphoma, but safety concerns remain.
The addition of rituximab to a short intensive chemotherapy regimen improved event-free survival in adult patients with Burkitt lymphoma or leukemia.
Anti-CD19 chimeric antigen receptor (CAR) T-cells were determined to be safe for further study in patients with refractory aggressive non-Hodgkin lymphoma.
Decreasing the frequency of infusions of romidepsin in patients with cutaneous T-cell lymphoma who achieve a response may prolong response.
The MATRix regimen may be the new standard chemoimmunotherapy for the treatment of central nervous system (CNS) lymphoma.
Routine Bone Marrow Biopsy Does Not Provide Prognostic, Diagnostic Value Over PET/CT in Most With DLBCL
Routine bone marrow biopsy (BMB) did not contribute relevant diagnostic or prognostic value over positron emission tomography (PET)/computed tomography (CT) alone.
CUDC-907 had an acceptable safety profile and demonstrated promising preliminary evidence of response in patients with diffuse large B-cell lymphoma.
Treatment of primary central nervous system lymphoma with methotrexate, TMZ, and rituximab, followed by hWBRT and subsequent TMZ was safe.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|